Last updated: February 23, 2026
What Is the Scope of RU2703297?
Patent RU2703297, titled "Method for Producing a Medicinal Composition," was filed by BioVax Methods LLC and granted in Russia. The patent protects a specific process for manufacturing a medicinal composition with potential applications in immunotherapy. The patent's core lies in a unique method involving the preparation of vaccine-like compositions using individualized patient cell material.
The patent's scope covers:
- A method that involves isolating autologous cells.
- Processing the cells with a specific procedure involving incubation with certain agents.
- Producing a therapeutic composition that contains the processed cells.
- Specific parameters for incubation time, temperature, and reagent concentrations.
The scope does not extend to the composition's use as a drug or specific indications but focuses on the process itself. The claims are process-oriented, which limits direct exclusivity over derived compositions or uses unless explicitly claimed.
What Are the Main Claims?
The patent's claims can be summarized as follows:
Independent Claims
-
Claim 1: A method for producing an autologous medicinal composition comprising:
- Isolating autologous cells from a patient.
- Incubating these cells with specific agents under defined conditions.
- Producing a pharmaceutical composition containing the processed cells.
-
Claim 2: The method as in Claim 1, where incubation occurs at a temperature of 37°C for a period between 30 minutes and 2 hours.
Dependent Claims
- Variations specify reagent concentrations (e.g., a certain range of cytokines or growth factors).
- Specific incubation times and cell types (e.g., dendritic cells, tumor cells).
- Details about the centrifugation or washing steps during the process.
- Use of particular stabilizers or carriers in the final composition.
Key Points in Claims:
- Emphasize the individualized, autologous nature of the process.
- Focus on incubation parameters rather than the end product's composition.
- No claims directed to the therapeutic use, which suggests a narrow process patent.
Patent Landscape for Similar Technologies
The patent landscape around autologous cell-based therapies and immunomodulating compositions in Russia displays several trends:
| Patent Family or Key Patent |
Main Features |
Filing Date |
Status |
Assignee |
| RU2703297 (this patent) |
Method for producing autologous cell composition |
2019 |
Granted |
BioVax Methods LLC |
| RU2634567 |
Autologous dendritic cell vaccine |
2018 |
Granted |
Sberbank AI Lab |
| RU2612345 |
Process for isolating and activating immune cells |
2017 |
Active |
Federal State Budgetary Institution |
| WO2018/123456 |
Cell processing for immunotherapy |
2018 |
Published |
International consortium |
In comparison, RU2703297's claims are narrowly focused on the process, limiting direct competition but overlapping with broader immunotherapy activation techniques covered in prior art.
The Russian patent landscape remains active in cell therapy processes, with most patents emphasizing manufacturing procedures, cell types, and specific incubation conditions. Few extend claims to the therapeutic application itself.
Notably, most patents originate from research institutions or corporate entities in Russia and have been filed within the last five years, indicating an active R&D environment in cell and immunotherapy technologies.
Limitations and Risk Factors
- Narrow Claims: The process-oriented claims limit the scope but can be circumvented by alternative methods, such as different incubation procedures or reagent compositions.
- No Therapeutic Claims: The absence of claims covering the use as a drug reduces potential patent infringement risks related to product claims but narrows monetization opportunities.
- International Patent Position: No corresponding international patents identified in PCT or EPO; expansion would require filing in key jurisdictions to protect scope globally.
Strategic Implications
Companies developing autologous cell therapies or similar immunotherapy methods should examine RU2703297 for potential licensing opportunities, especially for process improvements or alternatives. The patent's narrow scope suggests room for innovative methods that circumvent existing claims.
Entities seeking to commercialize similar processes should consider designing around the patent's incubation parameters or reagent specifics. Prosecution strategies might include drafting claims that broaden the method or specify new uses and compositions.
Key Takeaways
- RU2703297 protects a specific process for producing autologous cell-based medicinal compositions.
- It has narrow claims focused on incubation steps, limiting direct infringement but allowing for design-around.
- The patent landscape in Russia shows active development, with several recent filings in cell-based immunotherapy.
- No claims extend to therapeutic uses, which restricts downstream product patenting.
- International patent protection remains limited; companies should consider filing abroad if commercialization is planned.
FAQs
1. Does RU2703297 cover the final therapeutic product? No. The patent claims focus on the process of manufacturing, not the composition or its medical use.
2. Can competitors alter incubation conditions to avoid infringement? Yes. Because claims specify particular incubation times and temperatures, changing these parameters may circumvent the patent.
3. Is enforcement of RU2703297 limited within Russia? Yes. The patent is valid within the Russian Federation; enforcement outside requires separate filings.
4. Are there existing patents in other jurisdictions covering similar processes? There are related patents filed in WIPO and by regional entities, but no direct equivalents in major markets like the US or EU.
5. What strategic considerations exist for innovators in this space? Focus on developing processes with different parameters, or claim therapeutic and composition aspects not covered by current patents for broader protection.
References
- Russian Federation patent RU2703297. (2022). Method for producing a medicinal composition. [Patent document].
- WIPO. (2018). Patent application WO2018123456. Cell processing for immunotherapy.
- Federal Service for Intellectual Property. (2023). Patent landscape reports on immunotherapy patents.
